RA Capital-backed SPAC Research Alliance Corp III agrees to merge with Oak Hill Bio in USD 175 million deal

• Oak Hill Bio agreed to combine with Research Alliance Corporation III, creating a Nasdaq-listed rare-disease biotech expected to trade as OAKH.
• Deal implies about $175 million in gross proceeds, including $75 million from RACC’s trust account and a $100 million committed private financing.
• RA Capital funded $45 million at signing via a SAFE; the remaining amount is expected at closing through a PIPE priced at USD 10 per share.
• Closing is expected by year-end 2026; Oak Hill Bio CEO Josh Distler is set to lead the combined company.
• Cash is slated to advance rugonersen, an antisense therapy for Angelman syndrome, through Phase 3 readout and potential NDA submission in 2H2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Research Alliance Corporation III published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-316954), on July 27, 2026, and is solely responsible for the information contained therein.